Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Cytos To Fold After Phase II Failure

by Rick Mullin
April 21, 2014 | A version of this story appeared in Volume 92, Issue 16

Cytos Biotechnology has initiated the process of liquidating itself following the failure of its lead product candidate, CYT003, an asthma treatment in Phase II clinical trials. Cytos, which currently has 36 employees, underwent a significant downsizing in 2011, dropping other early-stage development projects and reducing staff from 82 to 10 workers. The company’s cash balance as of March 31 was $35 million.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.